Inhibitor-Protected Aminopenicillins. Pharmacological Characterization and Role in Community-Acquired Infections

1. Brown A. G., Butterworth D., Cole M. Naturally occurring beta-lactamase inhibitors with antibacterial activity. J Antibiot 1979; 29: 668—669.

2. English A. R., Retsema J. A., Girard A. E. et al. CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization. Antimicrob Agents Chemother 1978; 14: 3: 414—419.

3. Aronoff S. C., Jacobs M. R., Johenning S., Yamabe S. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. Ibid 1984; 26: 4: 580—582.

4. Barr W. H., Zola E. M., Candler E. L. et al. Differential absorption of amoxicillin from the human small and large intestine. Clin Pharmacol Ther 1994; 56: 3: 279—285.

5. Vree T. B., Dammers E., Exler P. S. Identical pattern of highly variable absorption of clavulanic acid from four different oral formulations of co-amoxiclav in healthy subjects. J Antimicrob Chemother 2003; 51: 2: 373-378.

6. Spyker D. A., Rugloski R. J., Vann R. L., O'Brien W. M. Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration. Antimicrob Agents Chemother 1977; 11: 1: 132—141.

7. Chulavatnatol S., Charles B. G. Determination of dose-dependent absorption of amoxicillin from urinary excretion data in healthy subjects. Br J Clin Pharmacol 1994; 38: 3: 274—277.

8. Nathwani D., Wood M. J. Penicillins. A current review of their clinical pharmacology and therapeutic use. Drugs 1993; 45: 6: 866—894.

9. Kaye C. M., Allen A., Perry S. et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin Ther 2001; 23: 4: 578—584.

10. Agerso H., Friis C. Penetration of amoxicillin into the respiratory tract tissues and secretions in pigs. Research in veterinary science 1998; 64: 3: 245—250.

11. Honeybourne D., Andrews J. M., Ashby J. P. et al. Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa. Thorax 1988; 43: 9: 715—719.

12. Gould I. M., Harvey G., Golder D. et al. Penetration of amoxycillin/clavulanic acid into bronchial mucosa with different dosing regimens. Ibid 1994; 49: 10: 999—1001.

13. Verbist L. Triple crossover study on absorption and excretion of ampicillin, pivampicillin, and amoxicillin. Antimicrob Agents Chemother 1974; 6: 5: 588-593.

14. Gordon R. C., Regamey C., Kirby W. M. M. Comparative clinical pharmacology of amoxicillin and ampicillin administered orally. Ibid 1972; 1: 6: 504—507.

15. Bodey G. P., Nance J. Amoxicillin: in vitro and pharmacological studies. Ibid 1972; 1: 4: 358—362.

16. Nilsson-Ehle I., Fellner H., Hedstrom S. A. et al. Pharmacokinetics of clavulanic acid, given in combination with amoxicillin, in volunteers. J Antimicrob Chemother 1985; 16: 4: 491—498.

17. Sourgens H., Steinbrede H., Verschoor J. S. et al. Bioequivalence study of a novel Solutab tablet formulation of amoxicillin/clavulanic acid versus the originator film-coated tablet. Intern J Clin Pharmacol Ther 2001; 39: 2: 75—82.

18. Cox A. L., Meewis J. M., Horton R. Penetration into lung tissue after intravenous administration of amoxycillin/clavulanate. J Antimicrob Chemother 1989; 24: Suppl B: 87—91.

19. Dinis P. B., Monteiro M. C., Martins M. L. et al. Sinus tissue pharmacokinetics after oral administration of amoxicillin/clavulanic acid. Laryngoscope 2000; 110: 6: 1050—1055.

20. Hampel B., Lode H., Bruckner G., Koeppe P. Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxicillin in human volunteers. Drugs 1988; 35: Suppl 7: 29—33.

21. Gill M. A., Kern J. W., Chenella F. C. et al. Pharmacokinetics of parenteral sulbactam in patients with appendicitis. Therapeutic drug monitoring. 1984; 6: 4: 428—431.

22. Kielstein J. T., Lorenzen J., Kaever V. et al. Risk of underdosing of ampicillin/sulbactam in patients with acute kidney injury undergoing extended daily dialysis — a single case. Nephrol Dial Transplant 2009; 18.

23. Foulds G., Knirsch A. K., Stankewich J. P., Weidler D. R. The parenteral kinetics of ampicillin/sulbactam in man. Intern J Clin Pharmacol 1985; 5: 2: 79—86.

24. Jacobs M. R. Building in efficacy: developing solutions to combat drug-resistant S.pneumoniae. Clin Microbiol Infect 2004; 10: Suppl 2: 18—27.

25. Cuffini A. M., Tullio V., Ianni Palarchio A. et al. Enhanced effects of amoxicillin/clavulanic acid compared with amoxicillin and clavulanic acid alone on the susceptibility to immunodefenses of a penicillin-resistant strain of Streptococcus pneumoniae. Drugs under experimental and clinical research 1998; 24: 4: 173-184.

26. Cuffini A. M., Tullio V., Allocco A. The antibacterial activity of amoxicillin/clavulanic acid against Staphylococcus aureus ingested by human granulocytes. Microbios 1996; 87: 350: 31—38.

27. Cuffini A. M., De Renzi G., Tullio V. et al. Potentiation of human polymorphonuclear leukocyte phagocytosis and intracellular bactericidal activity by amoxycillin/clavulanic acid. Drugs under experimental and clinical research 1996; 22: 1: 9—15.

28. Reato G., Cuffini A. M., Tullio V. et al. Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophils. Intern J Antimicrob Agents 2004; 23: 2: 150—154.

29. Tarrago D., Aguilar L., Gimenez M. J. et al. Effects of amoxicillin subinhibitory concentrations on the cross-protection developed by pneumococcal antibodies in mouse sepsis caused by an amoxicillin-resistant serotype 6B Streptococcus pneumoniae strain. Antimicrob Agents Chemother 2004; 48: 11: 4144—4147.

30. Lode H., Von der Hoh N., Ziege S. Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis 2001; 33: 12: 899—903.

31. Samonis G., Gikas A., Toloudis P. et al. Prospective study of the impact of broad-spectrum antibiotics on the yeast flora of the human gut. Eur J Clin Microbiol Infect Dis 1994; 13: 8: 665—667.

32. Грудинина С. A., Сидоренко C. В., Федорчук В. В. Динамика распространения антибиотикорезистентности среди Streptococcus pneumoniae в Москве в период с 1998 по 2003 гг. Антибиотики и химиотер 2004; 49: 4: 25—34.

33. Козлов Р. С., Сивая О. В., Шпынев К. В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999—2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и Пе-ГАС-II. Клин микробиол антимикроб химиотер 2006; 8: 1: 33—47.

34. Филимонова О. Ю., Грудинина C. A., Сидоренко С. В. и др. Антибиотико-резистентность штаммов Haemophilus influenzae, выделенных в Москве с 2002 по 2004 гг. Антибиотики и химиотер 2004; 49: 12: 14—20.

35. Sener B., Tunckanat F., Ulusoy S. et al. A survey of antibiotic resistance in Streptococcus pneumoniae and Haemophilus influenzae in Turkey, 2004 2005. J Antimicrob Chemother 2007; 60: 3: 587—593.

36. Farrell D. J., Couturier C. European survey of antibacterial activity against H. influenzae from 2006—2007: focus on fluoroquinolones [P2067]. Clin Microbiol Infect 2008; 14: Suppl 7.

37. Heilmann K. P., Rice C. L., Miller A. L. et al. Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States. Antimicrob Agents Chemother 2005; 49: 6: 2561—2564.

38. Zhanel G. G., Palatnick L., Nichol K. A. et al. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian respiratory organism susceptibility study, 1997 to 2002. Ibid 2003; 47: 6: 1875—1881.

39. Рафальский В. В., Малев И. В., Рохликов И. М., Деревицкий A. В. Рациональная антибактериальная терапия амбулаторных инфекций мочевыводящих путей с учётом данных по резистентности основных уропатогенов в России. Трудный пациент 2006; 49: 19—25.

40. Сидоренко С. В., Иванов Д. В. Результаты изучения распространения антибиотикорезистентности среди внебольничных возбудителей инфекций мочевыводящих путей в Москве. Фаза I. Антибиотики и химиотер 2005; 50: 1: 3—10.

41. Gill J. M., Fleischut P., Haas S. et al. Use of antibiotics for adult upper respiratory infections in outpatient settings: a national ambulatory network study. Family medicine 2006; 38: 5: 349—354.

42. Ashworth M., Charlton J., Ballard K. et al. Variations in antibiotic prescribing and consultation rates for acute respiratory infection in UK general practices 1995—2000. Br J Gen Pract 2005; 55: 517: 603—608.

43. Kuyvenhoven M., van Essen G., Schellevis F., Verheij T. Management of upper respiratory tract infections in Dutch general practice; antibiotic prescribing rates and incidences in 1987 and 2001. Family practice 2006; 23: 2: 175—179.

44. Varonen H., Rautakorpi U. M., Huikko S. et al. Management of acute maxillary sinusitis in Finnish primary care. Results from the nationwide MIKSTRA study. Scand J Primary Health Care 2004; 22: 2: 122—127.

45. Varonen H., Rautakorpi U. M., Nyberg S. et al. Implementing guidelines on acute maxillary sinusitis in general practice — a randomized controlled trial. Family practice 2007; 24: 2: 201—206.

46. Rosenfeld R. M., Singer M., Jones S. Systematic review of antimicrobial therapy in patients with acute rhinosinusitis. Otolaryngol Head Neck Surg 2007; 137: 3: Suppl: S32—45.

47. Young J., De Sutter A., Merenstein D. et al. Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a meta-analysis of individual patient data. Lancet 2008; 37: 9616: 908—914.

48. Колосов A. В., Гучев И. A., Кречикова О. И. Острый бактериальный риносинусит у военнослужащих: этиология, чувствительность к антибиотикам и эффективность антимикробной терапии. Клин микробиол антимикроб химиотер 2009; 11: 1: 14—21.

49. Страчунский Л. С, Тарасов А. А., Крюков А. И. и др. Возбудители острого бактериального синусита. Результаты многоцентрового микробиологического исследования SSSR. Там же 2005; 7: 4: 337—349.

50. Celin S. E., Bluestone C. D., Stephenson J. et al. Bacteriology of acute otitis media in adults. JAMA 1991; 266: 16: 2249—2252.

51. Pearlman A. N, Conley D. B. Review of current guidelines related to the diagnosis and treatment of rhinosinusitis. Current Opinion in Otolaryngology & Head and Neck Surgery 2008; 16: 3: 226—230.

52. Karageorgopoulos D. E., Giannopoulou K. P., Grammatikos A. P. et al. Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. CMAJ 2008; 178: 7: 845—854.

53. Feikin D. R., Schuchat A., Kolczak M. et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995—1997. Amer J Public Health 2000; 90: 2: 223—229.

54. Pallares R., Linares J., Vadillo M. et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. New England J Med 1995; 333: 8: 474—480.

55. Yu V. L., Chiou C. C., Feldman C. et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37: 2: 230—237.

56. Schrag S. J., McGee L., Whitney C. G. et al. Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob Agents Chemother 2004; 48: 8: 3016—3023.

57. File T. M., Garau J., Jacobs M. R., Wynne B. et al. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains. Intern J Antimicrob Agents 2005; 25: 2: 110—119.

58. Jacobs M. R. How can we predict bacterial eradication? Int J Infect Dis 2003; 7: Suppl 1: S13—20.

59. Singer M. E., Harding I., Jacobs M. R., Jaffe D. H. Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model. J Antimicrob Chemother 2003; 51: 5: 1269—1282.

60. Ortqvist A., Hedlund J., Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Seminars in respiratory and critical care medicine 2005; 26: 6: 563—574.

61. Mandell L. A., Wunderink R. G., Anzueto A. et al. Infectious diseases society of america/american thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl 2: S27—72.

62. Heffelfinger J. D., Dowell S. F., Jorgensen J. H. et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160: 10: 1399—1408.

63. Mandell L. A., Marrie T. J., Grossman R. F. et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31: 2: 383—421.

64. Macfarlane J., Boswell T. C., Douglas G. et al. BTS Guidelines for the management of community-acquired pneumonia in adults — 2004 update. Available at: http: //www. britthoracic. org. uk/guidelines. 2004.

65. ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Society. Eur Respir J 1998; 11: 4: 986—991.

66. Oosterheert J. J., Bonten M. J., Schneider M. M., Hoepelman I. M. Community acquired pneumonia: no reason to revise current Dutch antibiotic guidelines. Nederlands tijdschrift voor geneeskunde 2003; 147: 9: 381—386.

67. Чучалин А. Г., Синопальников А. И., Страчунский Л. С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Клин микробиол антимикроб химиотер 2006; 8: 1: 54—86.

68. Matsushima T. [The Japanese Respiratory Society Guidelines for the management of community-acquired pneumonia in adults — its spreading and results]. Nippon rinsho 2007; 65: Suppl 2 Pt. 1: 279—283.

69. Matsushima T. The Japanese Respiratory Society guidelines for management of community-acquired pneumonia in adults. Nippon rinsho 2003; 61: Suppl 2: 677—681.

70. Yanagihara K., Kohno S., Matsusima T. Japanese guidelines for the management of community-acquired pneumonia. Intern J Antimicrob Agents 2001; 18: Suppl 1: S45—48.

71. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Amer J Resp Crit Care Med 2005; 171: 4: 388—416.

72. van der Eerden M. M., Vlaspolder F., de Graaff C. S. et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60: 8: 672—678.

73. Johnson D., Carriere K. C., Jin Y., Marrie T. Appropriate antibiotic utilization in seniors prior to hospitalization for community-acquired pneumonia is associated with decreased in-hospital mortality. J Clin Pharm Ther 2004; 29: 3: 231—239.

74. Stahl J. E., Barza M., DesJardin J. et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159: 21: 2576—2580.

75. Tarsia P., Aliberti S., Pappalettera M., Blasi F. Mixed Community-acquired Lower Respiratory Tract Infections. Curr Infect Dis reports 2007; 9: 1: 14—20.

76. Guchev I. A., Yu V. L., Sinopalnikov A. et al. Management of nonsevere pneumonia in military trainees with the urinary antigen test for Streptococcus pneumoniae: an innovative approach to targeted therapy. Clin Infect Dis 2005; 40: 11: 1608—1616.

77. The OMBIRT Consensus Panel. Outpatient Management of Bacterial Infections in the Lower Respiratory Tract (OMBIRT): Diagnosis, Evaluation, and Antibiotic Selection in the Primary Care Setting. Atlanta, Ga: American Health Consultants; 2001.

78. Adams S. G., Melo J., Luther M., Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 5: 1345—1352.

79. Destache C. J., Dewan N., O'Donohue W. J. et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 43: Suppl A: 107—113.

80. Warren J. W., Abrutyn E., Hebel J. R. et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29: 4: 745—758.

81. Stratchounski L. S., Rafalsky V. L. Antimicrobial susceptibility of pathogens isolated from adult patients with uncomplicated community-acquired urinary tract infections in the Russian Federation: two multicentre studies, UTIAP-1 and UTIAP-2 Leonid S. Intern J Antimicrob Agents 2007; 28: Suppl 1: 4-9.

82. Рафальский В. В., Белокрысенко С. С., Козлов С. Н. и др. Чувствительность возбудителей мочевыводящих путей, выделенных в Российской Федерации, к пероральному цефалоспорину III поколения цефиксиму. Лечащий врач 2008; 8: 27—29.

83. Ahrenholz D. H. Necrotizing fascitis and other infections. In: Rippe JM, Irwin R. S., Alpert J. S., Fink M. P., eds. Intensive Care Medicine. 2nd ed. Boston: Little, Brown; 1991; 1334.

84. Kirby J. T., Mutnick A. H., Jones R. N. et al. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2002; 43: 4: 303—309.

85. Griego R. D., Rosen T., Orengo I. F., Wolf J. E. Dog, cat and human bites: a review. J Amer Acad Dermatol 1995; 33: 1019—1029.

86. Solomkin J. S., Bjornson H. S., Cainzos M. et al. A consensus statement on empiric therapy for suspected gram-positive infections in surgical patients. Am J Surg 2004; 187: 1: 134—145.

87. Kardas P. Non-compliance — some myths, some facts. Casopis lekaru ceskych 2004; 143: 8: 556—559; discussion 560.

88. Kardas P. Patient non-compliance as a cause of treatment failure. Pol Merkur Lekarski 2000; 9: 52: 732—735.

89. Pechere J. C., Hughes D., Kardas P., Cornaglia G. Non-compliance with antibiotic therapy for acute community infections: a global survey. Intern J Antimicrob Agents 2007; 29: 3: 245—253.

90. Kardas P. Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. J Antimicrob Chemother 2007; 59: 3: 531—536.

91. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. Ibid 2002; 49: 6: 897—903.

92. Claxton A. J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 8: 1296—1310.

93. Garau J., Twynholm M., Garcia-Mendez E. et al. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J Antimicrob Chemother 2003; 52: 5: 826—836.

94. Henry D. C., Riffer E., Sokol W. N. et al. Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob Agents Chemother 2003; 47: 9: 2770—2774.

95. Leophonte P., File T., Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respiratory medicine 2004; 98: 8: 708—720.

96. Arrieta J. R., Galgano A. S., Sakano E. et al. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis. Amer J otolaryngol 2007; 28: 2: 78—82.

97. Poirier R., Chardon H., Beraud A. et al. Efficacy and tolerability of pristinamycin vs amoxicillin-clavulanic acid combination in the treatment of acute community-acquired pneumonia in hospitalized adults. Revue de pneumologie clinique 1997; 53: 6: 325—331.

98. File T. M., Jr., Lode H., Kurz H. et al. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin -clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob Agents Chemother 2004; 48: 9: 3323—3331.

99. Neu H. C., Wilson A. P., Gruneberg R. N. Amoxicillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J Chemother (Florence, Italy)1993; 5: 2: 67—93.

100. Siquier B., Sanchez-Alvarez J., Garcia-Mendez E. et al. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2006; 57: 3: 536—545.

101. Calver A. D., Walsh N. S., Quinn P. F. et al. Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group. Clin Infect Dis 1997; 24: 4: 570—574.

102. Гучев И. A., Козлов Р. С. Безопасность и эффективность различных форм амоксициллина/клавулановой кислоты при инфекциях нижних дыхательных путей у взрослых: открытое, проспективное, рандомизированное исследование. Пульмонология 2008; 2: 73—80.